Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Aytu BioPharma Inc. (AYTU) had Revenue of $18.45M for the most recently reported fiscal quarter, ending 2025-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-03-31

Income Statement Financials
Revenue	$18.45M
Net Income	$3.99M
Cost of Goods Sold	$5.65M
Gross Profit	$12.81M
Operating Expenses	$16.03M
Operating Income	$2.42M
Non-Operating Income/Expense	$1.40M
Pre-Tax Income	$3.82M
Normalized Pre-Tax Income	$3.82M
Income after Taxes	$3.94M
Income from Continuous Operations	$3.94M
Consolidated Net Income/Loss	$3.99M
Normalized Income after Taxes	$3.94M
EBIT	$2.42M
EBITDA	$3.77M
Weighted-Average Shares Outstanding (Basic)	6.13M
Weighted-Average Shares Outstanding (Diluted)	8.20M
Earnings per Share (EPS) (Basic)	$0.65
Earnings per Share (EPS) (Diluted)	$0.21
Balance Sheet Financials
Current Assets	$72.51M
Property, Plant, and Equipment	$0.55M
Long-Term Assets	$51.69M
Total Assets	$124.20M
Current Liabilities	$70.71M
Long-Term Debt	$9.54M
Long-Term Liabilities	$18.60M
Total Liabilities	$89.30M
Common Equity	$34.90M
Tangible Shareholders Equity	$-13.81M
Shareholders Equity	$34.90M
Common Shares Outstanding	6.17M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-4.74M
Cash Flow from Investing Activities	$0.46M
Cash Flow from Financial Activities	$2.45M
Beginning Cash	$20.01M
End Cash	$18.17M
Increase/Decrease in Cash	$-1.83M
Stock-Based Compensation	$0.46M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.03
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.21
Debt to Equity Ratio	0.61
Gross Margin	69.40%
Operating Margin	13.12%
EBIT Margin	13.12%
EBITDA Margin	--
Pre-Tax Profit Margin	20.69%
Profit Margin	21.65%
Free Cash Flow	$-4.28M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.15
Inventory Turnover	0.51
Receiveable Turnover	0.52
Days Sales in Receivables	174.74
Return on Equity	11.29%
Return on Tangible Equity	-28.52%
Return on Assets	3.17%
Return on Investments	8.87%
Book Value Per Share	$5.66
Free Cash Flow per Share	$-0.52
Operating Cash Flow per Share	$-0.58

Data from Zacks Investment Research, Inc.